We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+64.75%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$415M
AUM Growth
-$87.3M
Cap. Flow
-$197M
Cap. Flow %
-47.49%
Top 10 Hldgs %
52.5%
Holding
125
New
21
Increased
12
Reduced
28
Closed
39

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$11.8M
2
PCVX icon
Vaxcyte
PCVX
+$9.81M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7M
4
RCUS icon
Arcus Biosciences
RCUS
+$3.8M
5
BTAI icon
BioXcel Therapeutics
BTAI
+$3.78M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.8M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.03M
3
GOSS icon
Gossamer Bio
GOSS
+$4.98M
4
SAGE
Sage Therapeutics
SAGE
+$3.44M
5
SCPH
scPharmaceuticals
SCPH
+$3.13M

Sector Composition

Rank Sector Weight
1 Healthcare 57.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BTAI icon
26
BioXcel Therapeutics
BTAI
$24.8M
$5.37M 1.3%
+15,625
New +$3.78M
VRNA
27
CALL
DELISTED
Verona Pharma
VRNA
$5.23M 1.26%
+200,000
New +$2.66M
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$4.51B
$5.17M 1.25%
325,000
– –
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.9M 1.18%
+108,100
New +$7M
ALT icon
30
Altimmune
ALT
$568M
$4.5M 1.09%
273,432
-198,622
-42% -$2.23M
KZR
31
DELISTED
Kezar Life Sciences
KZR
$4.44M 1.07%
62,999
-9,860
-14% -$731K
TCON
32
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$4.12M 0.99%
138,277
– –
ARDX icon
33
Ardelyx
ARDX
$1.24B
$3.93M 0.95%
1,378,825
-1,800,000
-57% -$3.05M
JBIO
34
Jade Biosciences
JBIO
$1.18B
$3.75M 0.9%
3,655
-2,059
-36% -$1.49M
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.64B
$3.67M 0.89%
28,324
+11,515
+69% +$1.33M
ARVN icon
36
CALL
Arvinas
ARVN
$530M
$3.42M 0.83%
100,000
– –
SGEN
37
DELISTED
Seagen Inc. Common Stock
SGEN
$3.21M 0.78%
+25,000
New +$3.23M
RCUS icon
38
Arcus Biosciences
RCUS
$3.33B
$2.85M 0.69%
+137,987
New +$3.8M
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$2.59M 0.62%
67,805
-90,000
-57% -$3.44M
ATXS
40
CALL
DELISTED
Astria Therapeutics
ATXS
$2.55M 0.61%
+171,100
New +$1.76M
MRUS
41
DELISTED
Merus
MRUS
$2.41M 0.58%
+156,000
New +$2.75M
VKTX icon
42
Viking Therapeutics
VKTX
$3.88B
$1.91M 0.46%
203,156
-260,000
-56% -$1.16M
MIST icon
43
Milestone Pharmaceuticals
MIST
$129M
$1.82M 0.44%
460,416
-395,200
-46% -$2.08M
GERN icon
44
CALL
Geron
GERN
$898M
$1.57M 0.38%
650,000
+150,000
+30% +$336K
PRQR icon
45
ProQR Therapeutics
PRQR
$244M
$1.56M 0.38%
+422,625
New +$554K
ABOS icon
46
Acumen Pharmaceuticals
ABOS
$152M
$1.38M 0.33%
254,945
-95,055
-27% -$639K
ARKG icon
47
ARK Genomic Revolution ETF
ARKG
$1.53B
$1.31M 0.32%
46,462
-50,000
-52% -$1.59M
LYRA
48
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.08M 0.26%
6,874
– –
ICPT
49
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.05M 0.25%
85,200
– –
PNT
50
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.02M 0.25%
139,565
-310,841
-69% -$2.31M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Ikarian Capital held 125 positions worth $415M, down 17% from $502M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Ikarian Capital withdrew a net $197M in Q4 2022, closing 39 positions and reducing 28 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $5.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 39% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Biohaven worth $11.6M.

  • Ikarian Capital's largest Q4 2022 buy was Biohaven: 837,500 shares worth $11.6M.
  • Ikarian Capital added most to Prometheus Biosciences, Inc. Common Stock in Q4 2022, an estimated $3.74M increase.
  • Ikarian Capital's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $12.8M.
  • Ikarian Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $5.03M.
  • Ikarian Capital's ten largest holdings make up 53% of its $415M portfolio in Q4 2022.
  • Ikarian Capital opened 21 new positions and closed 39 in Q4 2022.
  • Ikarian Capital's portfolio value fell 17% quarter-over-quarter to $415M.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.